Bibliografía del artículo
1. Fidler IJ, Ellis LM. Chemotherapeutic drugs- more really is not better. Nat Med 6:500-502, 2000.
2. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047, 2000.
3. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878:1886, 2000.
4. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-24, 2000.
5. Kerbel RS, Kamen BA The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436, 2004.
6. Folkman J. Endogenous angiogenesis inhibitors. APMIS 112:496-507, 2004.
7. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98:1619-1629, 2008.
8. Matar P, Rozados VR, Roggero EA, Bonfil RD, Scharovsky OG. Modulation of the antimetastatic response against a rat lymphoma by a single-low dose of Cyclophosphamide. Tumour Biol 19:69-76, 1998.
9. Matar P, Rozados VR, González AD, Dlugovitzky DG, Bonfil RD, Scharovsky OG. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer 36:1060-1066, 2000.
10. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG. Down regulation of T-cell derived IL-10 production by low-dose cyclophosphamide treatment in tumour-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol 1:307-319, 2001.
11. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG. Th2/Th1 switch induced by a single-low dose Cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 50:588-596, 2002.
12. Rozados VR, Sánchez AM, Gervasoni SI, Berra HH, Matar P, Scharovsky OG. Metronomic therapy with Cyclophosphamide induces rat lymphoma and sarcoma regression and is devoid of toxicity. Ann Oncol 15:1543-1550, 2004.
13. Calderari S, Font MT, Garrocq O, Martinez S, Morini JC, Puche R, Tarrés MC. The inbred IIM/Fm stock. Rat News Lett 25: 28-29, 1991.
14. Celoria GC, Hinrichsen LI, Font MT. Tumour behaviour of lymphoma TACB in rats resistant or susceptible to Sarcoma E-100. Com Biol (Bs Aires) 5:73-84, 1986.
15. Rozados VR, Mainetti LE, Rico MJ, Zacarías Fluck MF, Matar P, Scharovsky OG. Antiangiogenic and immunomodulatory effect of the metronomic therapy with Cyclophosphamide (Cy). Biocell 31:119-119, 2007.
16. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641-648, 2007.